The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL.[5]
Sheridan JP, Marsters SA, Pitti RM, et al. (1997). "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors". Science. 277 (5327): 818–21.
Sheikh MS, Huang Y, Fernandez-Salas EA, et al. (1999). "The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract". Oncogene. 18 (28): 4153–9.
Leverkus M, Walczak H, McLellan A, et al. (2000). "Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis". Blood. 96 (7): 2628–31.
Liao Q, Friess H, Kleeff J, Büchler MW (2002). "Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer". Anticancer Res. 21 (5): 3153–9.
Hueber A, Aduckathil S, Kociok N, et al. (2002). "Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells". Graefes Arch. Clin. Exp. Ophthalmol. 240 (7): 551–6.
Ruiz de Almodóvar C, López-Rivas A, Redondo JM, Rodríguez A (2002). "Transcription initiation sites and promoter structure of the human TRAIL-R3 gene". FEBS Lett. 531 (2): 304–8.
